Shandong Boan Biotechnology Co., Ltd. (HKG: 6955)
Hong Kong
· Delayed Price · Currency is HKD
9.90
+0.18 (1.85%)
Oct 10, 2024, 3:58 PM HKT
Shandong Boan Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 719.84 | 618.13 | 515.96 | 158.7 | - |
| Revenue Growth (YoY) | 29.35% | 19.80% | 225.11% | - | - |
| Cost of Revenue | 186.46 | 209.16 | 161.73 | 52.19 | - |
| Gross Profit | 533.38 | 408.97 | 354.23 | 106.51 | - |
| Selling, General & Admin | 323.09 | 308.22 | 296.42 | 96.21 | 4.46 |
| Research & Development | 190.45 | 230.68 | 400.34 | 231.57 | 236.32 |
| Operating Expenses | 513.55 | 538.9 | 696.76 | 327.78 | 240.78 |
| Operating Income | 19.83 | -129.93 | -342.53 | -221.27 | -240.78 |
| Interest Expense | -20.43 | -14.09 | -13.41 | -11.6 | -11.82 |
| Interest & Investment Income | 0.36 | 1.16 | 5.57 | 9.1 | 1.2 |
| Currency Exchange Gain (Loss) | - | - | 2.38 | - | - |
| Other Non Operating Income (Expenses) | 61.81 | 23.49 | 16.24 | -1.65 | 10.88 |
| EBT Excluding Unusual Items | 61.57 | -119.38 | -331.75 | -225.42 | -240.53 |
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 |
| Pretax Income | 61.57 | -119.38 | -331.75 | -225.42 | -240.54 |
| Net Income | 61.81 | -119.38 | -331.75 | -225.42 | -240.54 |
| Net Income to Common | 61.81 | -119.38 | -331.75 | -225.42 | -240.54 |
| Shares Outstanding (Basic) | 509 | 509 | 499 | 479 | 39 |
| Shares Outstanding (Diluted) | 509 | 509 | 499 | 479 | 39 |
| Shares Change (YoY) | 1.06% | 2.14% | 4.19% | 1119.88% | - |
| EPS (Basic) | 0.12 | -0.23 | -0.67 | -0.47 | -6.13 |
| EPS (Diluted) | 0.12 | -0.23 | -0.67 | -0.47 | -6.13 |
| Free Cash Flow | -104.51 | -85.89 | -283.13 | -354.01 | -531.77 |
| Free Cash Flow Per Share | -0.21 | -0.17 | -0.57 | -0.74 | -13.55 |
| Gross Margin | 74.10% | 66.16% | 68.65% | 67.11% | - |
| Operating Margin | 2.76% | -21.02% | -66.39% | -139.42% | - |
| Profit Margin | 8.59% | -19.31% | -64.30% | -142.04% | - |
| Free Cash Flow Margin | -14.52% | -13.90% | -54.87% | -223.06% | - |
| EBITDA | 60.72 | -76.34 | -292.56 | -188.72 | -227.68 |
| EBITDA Margin | 8.44% | -12.35% | -56.70% | -118.91% | - |
| D&A For EBITDA | 40.89 | 53.59 | 49.97 | 32.55 | 13.1 |
| EBIT | 19.83 | -129.93 | -342.53 | -221.27 | -240.78 |
| EBIT Margin | 2.76% | -21.02% | -66.39% | -139.42% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.